Amibegron

A selective β₃ adrenergic receptor agonist

Amibegron (also known by its developmental code name SR-58611A) is a pharmaceutical compound that acts as a selective [[β₃ adrenergic receptor]] agonist. It was under investigation for its potential use in the treatment of depression and anxiety disorders.

Pharmacology

Amibegron is a selective agonist for the [[β₃ adrenergic receptor]], a type of adrenergic receptor that is primarily found in adipose tissue and the gastrointestinal tract. Activation of these receptors leads to increased lipolysis and thermogenesis, which are processes involved in the breakdown of fat and the production of heat, respectively.

Chemical structure of Amibegron

The pharmacological action of amibegron is distinct from that of other adrenergic receptor agonists, which typically target the [[β₁]] and [[β₂]] adrenergic receptors. By selectively targeting the β₃ receptor, amibegron was hypothesized to have fewer cardiovascular side effects compared to non-selective adrenergic agonists.

Potential Therapeutic Uses

Amibegron was primarily investigated for its potential use in treating depression and anxiety disorders. The rationale for this was based on the role of the β₃ adrenergic receptor in modulating neurotransmitter release and neuroplasticity, which are processes implicated in mood regulation.

In preclinical studies, amibegron demonstrated anxiolytic and antidepressant-like effects in animal models. These findings suggested that amibegron could be a novel therapeutic option for patients with mood disorders, offering a different mechanism of action compared to traditional antidepressants and anxiolytics.

Development and Clinical Trials

Amibegron was developed by Sanofi-Aventis and underwent several phases of clinical trials. However, despite initial promising results, the development of amibegron was eventually discontinued. The reasons for discontinuation were not publicly detailed, but it is common for drug development to be halted due to factors such as lack of efficacy, safety concerns, or strategic business decisions.

Mechanism of Action

The mechanism of action of amibegron involves the selective activation of the β₃ adrenergic receptor. This receptor subtype is coupled to G-proteins that activate adenylate cyclase, leading to an increase in cyclic adenosine monophosphate (cAMP) levels. The rise in cAMP activates protein kinase A (PKA), which in turn phosphorylates target proteins that mediate the physiological effects of β₃ receptor activation.

Related pages

• Adrenergic receptor
• Depression (mood disorder)
• Anxiety disorder
• Lipolysis